Analysis of tumor DNA markers in the plasma of cancer patients by liquid biopsy

Analysis of tumor DNA markers in the plasma of cancer patients by liquid biopsy - Liquid Biopsy in cancer patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012890

Enrollment

250

Registered

2017-09-14

Start date

2018-10-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C18 C20 C50 C34 C61 C19 C56

Interventions

Group 1: Blood samples as well as paraffin-embedded tumour tissue from patients with solid tumours are to be examined using liquid biopsy methods before the start of therapy and during the course of t

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: solid tumor disease

Exclusion criteria

Exclusion criteria: - Therapy (surgery or neoadjuvant therapy) has already started - pregnancy

Design outcomes

Primary

Measure	Time frame
Detection of tumor-specific markers in the patient's blood serum before therapy	—

Secondary

Measure	Time frame
Detection of tumor-specific markers in the patient's blood serum over the course of the disease	—

Countries

Germany

Contacts

Public ContactVerena Steinke-Lange

Medizinisch Genetisches Zentrum (MGZ)

verena.steinke-lange@mgz-muenchen.de+49 (0)89/30 90 886-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 13, 2026